Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Stocks To Watch: Retail Heavyweights To Center Stage

2018-02-17 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (603-3)

ROTY Edition 1 Volume 80: Adding To Select Positions And Continuing To Manage Risk

2018-02-16 seekingalpha
I remind readers of our biggest loser to date and why risk management has been key to ROTY`s success. (146-0)

ROTY Edition 1 Volume 79: Limited Downside Catalysts Vs. Binary Risk

2018-02-14 seekingalpha
We discuss the difference between binary catalysts and those with limited downside, utilizing two recent examples. (166-3)

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

2018-02-13 seekingalpha
As always, readers are encouraged to do their own due diligence, manage risk appropriately, and avoid blindly following. (313-2)

JAZZ / Jazz Pharmaceuticals, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 5 JAZZ PHARMACEUTICALS PLC COMMON STOCK Cusip #G50871105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G50871105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 482,314 Item 6: 0 Item 7: 7,040,871 Item 8: 0 Item 9: 7,040,871 Item 11: 11.

JAZZ / Jazz Pharmaceuticals, Inc. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 5 JAZZ PHARMACEUTICALS PLC COMMON STOCK Cusip #G50871105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G50871105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 482,314 Item 6: 0 Item 7: 7,040,871 Item 8: 0 Item 9: 7,040,871 Item 11: 11.

Your Daily Pharma Scoop: GW Pharmaceuticals Pullback, Seattle Genetics Announces Collaboration Agreement, Catalyst Reports Data

2018-02-10 seekingalpha
Today we will discuss GW Pharmaceuticals (GWPH), which after a solid run over the past six months has seen a sharp pullback in its shares during the recent sell-off in the broader market. (140-3)

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

2018-02-09 seekingalpha
Recent market volatility is addressed and we discuss in depth how to react while sticking to one´s plan. (192-1)

JAZZ / Jazz Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
jazzpharmaceuticalsplc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Jazz Pharmaceuticals PLC     Title of Class of Securities:  Common Stock     CUSIP Number:  G50871105     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is file

JAZZ / Jazz Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-08 sec.gov
jazzpharmaceuticalsplc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Jazz Pharmaceuticals PLC     Title of Class of Securities:  Common Stock     CUSIP Number:  G50871105     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is file

Valeant Pharmaceuticals on the Street: Analyst Ratings This February

2018-02-08 editors.aws.marketrealist
Valeant Pharmaceuticals (VRX) is a specialty pharmaceutical company involved in the development, manufacture, and marketing of branded, generic, branded generic as well as over the counter products. The company is also into medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. (11-0)

JAZZ / Jazz Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-07 fintel.io
Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) has 428 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 56,078,725 shares. Largest shareholders include Putnam Investments Llc, FMR LLC / Fidelity, Vanguard Group Inc, BlackRock Inc., JP Morgan Chase & Co, Bank of New York Mellon Corp, Westfield Capital Management Co Lp, Senator Investment Group LP, Renaissance Technologies LLC, and Boston Partners. (35-0)

JAZZ / Jazz Pharmaceuticals, Inc. / PUTNAM INVESTMENTS LLC - 3G/A (Passive Investment)

2018-02-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) JAZZ PHARMACEUTICALS PLC -------------------------------------------------------------------------------- (Name of Issuer) Common -------------------------------------------------------------------------------- (Title of Class of Securities) G50871105 -------------------------------------------------------------------------------- (CUSIP Number) Decembe

JAZZ / Jazz Pharmaceuticals, Inc. / PUTNAM INVESTMENTS LLC - 3G/A (Passive Investment)

2018-02-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) JAZZ PHARMACEUTICALS PLC -------------------------------------------------------------------------------- (Name of Issuer) Common -------------------------------------------------------------------------------- (Title of Class of Securities) G50871105 -------------------------------------------------------------------------------- (CUSIP Number) Decembe

ImmunoGen Price Run Up Driven By Potential Clinical Trial Data

2018-02-06 seekingalpha
ImmunoGen (IMGN) is a clinical-stage biotechnology company focused on cancer treatments. The stock price has been on a roll this year, rising from a 52-week low of $2.30 per share on February 8, 2017, to a 52-week high of $10.04 on February 2, 2018. (30-0)


CUSIP: G50871105